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gestions of new foods or medications; however she had reported mild
intermittent headaches over the week prior to admission. She was afe-
brilewith stable vital signs. Computed tomography scan of thehead, com-
plete blood count, comprehensive metabolic proﬁle, thyroid stimulating
hormone, beta human chorionic gonadotropin, acetaminophen level, al-
cohol level, salicylate level, urinalysis and urine toxicology were all
unrevealing. Shewas determined to bemedically cleared andwas admit-
ted to inpatient psychiatry service for acute psychosis.
During three days of psychiatric hospitalization, her condition de-
clined despite multiple anti-psychotic medications. She became nonver-Fairfax Hospital emergency department where she was found to have1. Introduction
Anti- N-methyl-D-aspartate (NMDA)-receptor encephalitis is a
recently described syndrome of psychiatric symptoms and neurologic
sequelae associated with ovarian teratomas. Due to the rarity of anti-
NMDA-receptor encephalitis, diagnosis may be delayedwhile more com-
mon conditions, such as primary psychiatric disorders and infectious
encephalitis, are ruled out. With correct diagnosis, and treatment includ-
ing resection of the teratoma and adjunctive immunotherapy, favorable
outcomes may be achieved. Patients may require prolonged monitoring
for development of teratoma, andmust be counseled on appropriate con-
traceptive use if remaining on long-term immunosuppression.2. Case
A 12 year-old previously healthy pre-menarchal female presented to
the emergencydepartmentwith her parentswith a one-dayhistory of ab-
normal behavior. They reported that she started experiencing auditory
hallucinations then became increasingly emotionally labile and confused,
all within a 24-h period. On presentation to the emergency department,
shewas crying, speaking incoherently, and complaining of auditory hallu-and Gynecology, The George
, Suite 6A429, Washington, DC
rman).
. This is an open access article underbal, unable to swallow, and incontinent. She was brought to the Inova
constricted and minimally reactive pupils. She was obtunded and unable
to respond to commands. The remainder of her exam, including abdomi-
nal exam, was within normal limits. Brain magnetic resonance imaging
(MRI) showed no abnormalities. Shewas admitted for further evaluation.
Lumbar puncture demonstrated elevated lymphocytes consistent with
autoimmune encephalitis or viral meningitis. Cerebrospinal ﬂuid (CSF)
and serum viral polymerase chain reaction and autoimmune encephalitis
studies were obtained. While this workup was being completed, she be-
came febrile, tachycardic, and required intubation. Due to a high index
of suspicion for autoimmune encephalitis, including anti-NMDA-receptor
encephalitis, an abdominal ultrasound was ordered to evaluate for ovari-
an teratoma. Ultrasound demonstrated an 11.1 × 6.6 × 8.1 cm complex
cystic and solid mass arising from the left ovary (Fig. 1).
Although results were not yet available from anti-NMDA-receptor
antibody studies of the patient's CSF, her failure to respond to anti-
psychotics and development of progressive neurological signs and
symptoms, CSF lymphocytosis, and the ﬁnding of a mass consistent
with teratomawere highly concerning for anti-NMDA-receptor enceph-
alitis. Given the rapid deterioration in the patient's condition despite
supportive care, the decision was made to remove her adnexal mass
in hopes of preventing further disease progression. She underwent ex-
ploratory laparotomy, left salpingo-oophorectomy, small bowel mesen-
teric lymph node biopsy, staging peritoneal biopsies, and partial
omentectomy. The patient's left ovary had been fully replaced by the
complexmass seen intact in Fig. 2 and in cross-section in Fig. 3. Final pa-
thology of surgical specimens revealed a mature teratoma without any
evidence of malignancy. CSF studies later demonstrated anti-NMDA-re-
ceptor antibodies, conﬁrming her diagnosis.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Ultrasound image of left adnexa showing 11 cm complex cystic and solid mass re-
placing left ovary.
Fig. 3. Cross-section of left ovarian mass, demonstrating multiple tissue types consistent
with ﬁnal diagnosis of mature teratoma.
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version of the BrainWorks protocol for severe antibody-mediated in-
ﬂammatory brain disease. Treatment included intravenousmethylpred-
nisolone, intravenous immunoglobulins, and rituximab, in addition to
routine supportive care. By post-operative day six, she was extubated.
She had substantial autonomic instability characterized by tachycardia
and fevers, but mental status slowly improved. Two weeks post-
operatively, she started opening her eyes. She began tracking faces
and to making an effort to smile when asked to do so. By three weeks
post-operatively, she was following basic commands, responding to
yes/no questions and attempting to speak. By one month post-
operatively, she was oriented, able to converse clearly without difﬁcul-
ty, follow all commands and answer questions appropriately, though
she was mildly impulsive and required prompting to complete tasks.
She was transferred to inpatient rehabilitation exactly one month
post-operatively to continue her recovery. At six months post-
operatively, the patient had resumed all of her normal activities and
was achieving straight-As in school.Fig. 2. Intact left ovarian mass.3. Comment
Anti-NMDA-receptor encephalitis was initially described in 1997, in
two separate reports of youngwomen. Thesewomenpresentedwith an
ovarian teratoma and symptoms that included psychiatric manifesta-
tions and altered level of consciousness. In both patients, there was a
gradual signiﬁcant improvement in symptoms after tumor removal
(Nokura et al., 1997; Okamura et al., 1997). In 2005, a series of four
women with ovarian teratoma, psychiatric symptoms, altered level of
consciousness and central hypoventilation was described. Authors
hypothesized that the syndrome was a paraneoplastic process due to
an antibody to an unknown antigen expressed in the hippocampus
(Vitaliani et al., 2005). The associated antibody was discovered to be
anti-NMDA-receptor in 2007 (Dalmau and Tüzün, 2007). In subsequent
years, hundreds of cases have been reported in the neurology literature
in both men and women, with approximately 80% of cases in females
(Mann et al., 2014). The median age at onset of symptoms is 21 years
old, although cases have been reported in patients ranging from 8
months to 85 years (Titulaer et al., 2013; Dalmau et al., 2011). Terato-
mas are found in large numbers of patients, most commonly in
women between age 12 and 45 and in patients of Asian or African
American descent (Titulaer et al., 2013; Dalmau et al., 2011). Most com-
monly, these are ovarian teratomas, though other germ-cell and rarely
non-germ cell tumors have also been described in association with
anti-NMDA-receptor encephalitis (Dalmau and Tüzün, 2007; Titulaer
et al., 2013; Dalmau et al., 2011). Three cases have been described in
pregnant women, all of whom recovered after removal of their ovarian
teratoma and immunosuppression. Two of these women went on to
have healthy infants, while one underwent termination of pregnancy
(Kumar et al., 2010).
The syndrome often begins with viral-like symptoms including
headache, nausea, vomiting, fever, and fatigue (Dalmau et al., 2011).
The non-speciﬁc nature of these symptoms generally precludes diagno-
sis at this stage and is recognized as a prodrome only after the illness
progresses with a spectrum of neuropsychiatric symptoms. These
symptoms have been divided into early and late stage symptoms.
Early stage symptoms generally present with two weeks of prodromal
symptoms and include confusion, memory loss, paranoia, hallucina-
tions, mood disturbances, anxiety, self-harming behaviors, seizures
and movement disorders such as facial twitching and choreoathetosis
(Dalmau et al., 2011). As the psychiatric symptoms are often the most
prominent, 77% of patients are initially seen by psychiatrists (Mann
et al., 2014), andmany patients are diagnosedwith new-onset psychiat-
ric disorders. However, these patients do not respond to anti-psychotics
and progress to late stage symptoms, such as decreased responsiveness,
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hypertension, bradycardia or tachycardia, hyperthermia, and urinary in-
continence (Mann et al., 2014).
In patients with acute onset of psychiatric symptoms with any neu-
rologic ﬁndings, or symptoms unresponsive to anti-psychotic medica-
tions, the diagnosis of encephalitis should be considered. In particular,
serum and CSF studies for markers of viral and autoimmune causes of
encephalitis, MRI, and electroencephalogram (EEG) may be useful in
obtaining a diagnosis. Of note, while MRI may be normal in two-thirds
of patients with anti-NMDA-receptor encephalitis, EEG abnormalities
are seen inmore than 90% of these patients (Titulaer et al., 2013). Deﬁn-
itive diagnosis is made when anti-NMDA-receptor antibodies are de-
tected in the blood or CSF (Titulaer et al., 2013; Dalmau et al., 2011).
Once deﬁnitive diagnosis has been obtained, imaging studies such as
pelvic ultrasound, MRI, computed tomography, and positron emission
tomography may be used to evaluate for an underlying teratoma. In
rapidly-deterioratingpatients inwhomanti-NMDA-receptor encephali-
tis is highly suspected, but not yet conﬁrmed, providers may consider
imaging and removal of any detected neoplasms, as in this case. Delayed
treatment may result in progression of the autoimmune process with
associated clinical deterioration to autonomic instability, catatonia,
status epilepticus, or coma. In one series of patients with anti-
NMDA-receptor encephalitis, ﬁve out of six patients with an ovarian
teratoma who did not undergo surgery died (Titulaer et al., 2013). In
contrast, removal of the tumor may be curative. In approximately 80%
of patients who undergo tumor removal and immunosuppressive treat-
ment, substantial neurological improvement occurs (Dalmau et al.,
2011). In the case above and in previously reported cases, symptoms
of anti-NMDA-receptor encephalitis markedly improved within one
month of tumor removal and immunosuppressive treatment, though
recovery can continue for up to 24 months (Titulaer et al., 2013;
Dalmau et al., 2011).
Multiple regimens of immunosuppressive treatments have been de-
scribed, including ﬁrst line treatment with intravenous steroids and in-
travenous immunoglobulins (IVIG) or plasmapheresis and second line
treatment with rituximab and cyclophosphamide (Titulaer et al.,
2013; Dalmau et al., 2011). For the patient described above, a modiﬁed
version of the BrainWorks protocol for severe antibody-mediated in-
ﬂammatory brain diseasewasused (BrainWorks). This protocol consists
of 1 g prednisone daily for three to seven days, followed by 60mg daily
for onemonth, followed by a six-month taper. Simultaneously, patients
receive seven plasmapheresis treatments over 14 days, 70 g of IVIG
every two weeks for ﬁve doses, rituximab 500 mg/m2 in two doses
two weeks apart, and daily calcium and vitamin D supplementation.
This protocol was developed by the BrainWorks Network based on ex-
perience from a web-based, international prospective cohort of pediat-
ric patients with inﬂammatory brain diseases. It differs from previously
described protocols (Titulaer et al., 2013; Dalmau et al., 2011) in that it
is based solely on experience in the pediatric population, and includes
rituximab in the initial treatment, rather than using it as a second line
agent.
In patients with no detectable underlying neoplasms, it has been hy-
pothesized that the syndrome may be caused by microscopic germ cell
tumors undetectable by imaging (Mann et al., 2014). This hypothesis is
supported by the ﬁndings that recovery is more common and relapse
less likely in patients with a detectable tumor (Dalmau et al., 2011). Inaddition, there have been reported cases of ovarian teratomas being de-
tected years after presentation of anti-NMDA-receptor encephalitis
symptoms (Mann et al., 2014). Therefore, for patients without detect-
able tumors, it is recommended to continue immunosuppression with
azathioprine or mycophenolate for a minimum of 1 year after symptom
relapse, and in female patients over age 12 without detectable tumors,
to screen for ovarian teratomas with pelvic MRI or ultrasound every 6
months for 4 years (Mann et al., 2014; Titulaer et al., 2013; Dalmau
et al., 2011).
Following neurologic recovery, women of childbearing potential
should receive counseling on contraception, particularly for those re-
maining on azathioprine and mycophenolate. These medications are
both classiﬁed as Pregnancy Category D. These women should have a
pregnancy test prior to treatment initiation and as indicated at follow
up visits. For mycophenolate in particular, it is recommended to avoid
pregnancy for an additional 6 weeks following discontinuation of treat-
ment. Particular consideration should be given to use of long-acting re-
versible contraceptives in these patients given that many may have
residual cognitive deﬁcits including difﬁculties with memory and im-
pulsivity that maymake consistent contraceptive usemore challenging.
With appropriate diagnosis and rapid treatment, including resection
of any underlying teratoma and immunosuppression, patients with
anti-NMDA-receptor encephalitis have a high likelihood of a positive
outcome. The gynecologist has an important role to play within the
multidisciplinary team caring for these patients as early tumor detec-
tion and removal results in an improved prognosis, and those without
tumors require frequent monitoring for tumor development.
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